Transferrin, C(3) Complement, Haptoglobin,
Plasminogen and α(2) -Macroglobulin in Patients with Urogenital Tumors

Dunzendorfer, U; Jung, Kyeong-Ah; Ohlenschläger, G

doi:10.1159/000473339

Cited by 22 publications

(14 citation statements)

References 9 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Humoral measures, such as concentrations of Igs and complement pro teins, were also increased 6 months after initiating IFN therapy compared to values prior to treatment. The increase in C3 con centrations found by us is in agreement with the results of Dunzendorfer et al [23]. These authors also interpret this phenomenon as an indicator for immune system activation.…”

Section: Discussionsupporting

confidence: 93%

Immunomonitoring in Treatment of Metastatic Renal Cell Carcinoma with Interferon Gamma

Goepel¹,

Otto²,

Möllhoff³

et al. 1995

Oncol Res Treat

View full text Add to dashboard Cite

Background: Metastatic renal cancer is considered not to benefit from treatment by present-day methods. Clinical and experimental experience lead to the suggestion that mechanisms exerted by the immune system favour the outcome of patients with metastatic renal carcinoma. Immunomodulating therapy with interferon-gamma has been proved to be clinically effective in etastatic renal carcinoma. Material and Methods: A non-randomized phase-II study was initiated to observe the clinical and immunological effects of 200 μg interferon-gamma (IFN-gamma) s. c. once weekly in patients with metastatic renal carcinoma. Twenty patients were enrolled in this study. The protocol was accepted by the Ethical Committee of the Medical Faculty, University of Essen. Clinical data, cellular and humoral immune system parameters were monitored over 6 months. Results: Median survival of the patients was 12 months. No complete or partial remission could be documented. We observed a significant increase in lymphocyte, B, T, T helper and natural killer (NK) cell counts after 6 months of treatment compared to the appropriate pretreatment values. Concentrations of complement C3, C4 and immunoglobulins (Ig) A, IgG and IgM were also significantly increased after treatment with IFN-gamma. Pretreatment values of B, T, T helper and NK cells were decreased and complement serum values were increased in comparison to normal values. Conclusion: Although a significant increase of the investigated immunologie parameters after IFN-gamma therapy could be seen, no clinical remission was associated with this treatment modality. The validity and usefulness of immunomonitoring in metastatic renal cancer has to be discussed again.

show abstract

Section: Discussionsupporting

confidence: 93%

Immunomonitoring in Treatment of Metastatic Renal Cell Carcinoma with Interferon Gamma

Goepel¹,

Otto²,

Möllhoff³

et al. 1995

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Furthermore, Dunzendorfer et al (1980) found increased serum haptoglobin levels in patients with urogenital tumors. Only haptoglobin phenotype has been examined in patients with bladder cancer, as observed in a study by Benkmann et al (1987).…”

Section: Discussionmentioning

confidence: 93%

“…Haptoglobin levels have been investigated in various malignant tumors, including lung cancer (Beckman et al, 1986), breast cancer (Awadallah et al, 2004), urogenital tumors (Dunzendorfer et al, 1980) and esophageal squamous cell carcinoma . The haptoglobin phenotype in patients with bladder cancer was reported in a study by Benkmann et al (1987).…”

Section: Introductionmentioning

confidence: 99%

Haptoglobin Levels in Turkish Patients with Bladder Cancer and its Association with Clinicopathological Features

Kaba

Pirinççi

Benli̇³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…11,14) It is produced in the liver and immunological cells and secreted into serum. Its level changes in the serum in response to infection, inflammation, and various malignant diseases, including lung and bladder cancer, 15,16) leukemia, 17) breast cancer, 18) malignant lymphoma, 19) urogenital tumors, 20) and esophageal squamous cell carcinoma. 21) Of these 41 genes, we especially observed Hp gene.…”

Section: Haptoglobin Proved a Prognostic Biomarker In Peripheral Bloomentioning

confidence: 99%

Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer

Pang

Tashiro

Eguchi

et al. 2013

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

Transferrin, C(3) Complement, Haptoglobin, Plasminogen and α(2) -Macroglobulin in Patients with Urogenital Tumors

Cited by 22 publications

References 9 publications

Immunomonitoring in Treatment of Metastatic Renal Cell Carcinoma with Interferon Gamma

Immunomonitoring in Treatment of Metastatic Renal Cell Carcinoma with Interferon Gamma

Haptoglobin Levels in Turkish Patients with Bladder Cancer and its Association with Clinicopathological Features

Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About